+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Immune Checkpoint Inhibitor"

Oncolytic Virus - Competitive Landscape, 2026 - Product Thumbnail Image

Oncolytic Virus - Competitive Landscape, 2026

  • Report
  • January 2026
  • 250 Pages
  • Global
From
CTLA-4 Inhibitors - Competitive Landscape, 2026 - Product Thumbnail Image

CTLA-4 Inhibitors - Competitive Landscape, 2026

  • Report
  • January 2026
  • 220 Pages
  • Global
From
PD-1 and PD-L1 Inhibitors - Competitive Landscape, 2026 - Product Thumbnail Image

PD-1 and PD-L1 Inhibitors - Competitive Landscape, 2026

  • Report
  • January 2026
  • 400 Pages
  • Global
From
TIGIT Inhibitors - Competitive Landscape, 2026 - Product Thumbnail Image

TIGIT Inhibitors - Competitive Landscape, 2026

  • Report
  • January 2026
  • 100 Pages
  • Global
From
From
Antibody Drug Conjugate - Competitive Landscape, 2026 - Product Thumbnail Image

Antibody Drug Conjugate - Competitive Landscape, 2026

  • Report
  • April 2026
  • 280 Pages
  • Global
From
From
Checkpoint Inhibitors - Competitive Landscape, 2026 - Product Thumbnail Image

Checkpoint Inhibitors - Competitive Landscape, 2026

  • Report
  • January 2026
  • 180 Pages
  • Global
From
Monoclonal Antibodies - Competitive Landscape, 2026 - Product Thumbnail Image

Monoclonal Antibodies - Competitive Landscape, 2026

  • Report
  • January 2026
  • 450 Pages
  • Global
From
From
From
Monoclonal Antibodies for Oncology: Global Markets - Product Thumbnail Image

Monoclonal Antibodies for Oncology: Global Markets

  • Report
  • February 2026
  • 229 Pages
  • Global
From
Immunotherapy Drugs: Global Markets - Product Thumbnail Image

Immunotherapy Drugs: Global Markets

  • Report
  • November 2025
  • 231 Pages
  • Global
From
From
HER2 Positive Gastric Cancer Pipeline Analysis Report 2026 - Product Thumbnail Image

HER2 Positive Gastric Cancer Pipeline Analysis Report 2026

  • Report
  • May 2026
  • 150 Pages
  • Global
From
Thymic Carcinoma Pipeline Analysis Report 2026 - Product Thumbnail Image

Thymic Carcinoma Pipeline Analysis Report 2026

  • Report
  • May 2026
  • 200 Pages
  • Global
From
From
Malignant Mesothelioma Drug Pipeline Analysis Report 2026 - Product Thumbnail Image

Malignant Mesothelioma Drug Pipeline Analysis Report 2026

  • Drug Pipelines
  • May 2026
  • 150 Pages
  • Global
From
Liver Cancer Drug Pipeline Analysis Report 2026 - Product Thumbnail Image

Liver Cancer Drug Pipeline Analysis Report 2026

  • Drug Pipelines
  • May 2026
  • 150 Pages
  • Global
From
Loading Indicator

Immune Checkpoint Inhibitor drugs are a type of immunotherapy used to treat immune disorders. They work by blocking proteins that act as “checkpoints” in the immune system, allowing the body to recognize and attack cancer cells. These drugs are used to treat a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. They are also used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease. Immune Checkpoint Inhibitor drugs are a relatively new form of treatment, and the market is still in its early stages. However, the potential of these drugs has led to a surge in research and development, with many companies investing in the development of new drugs. Some of the major companies in the Immune Checkpoint Inhibitor market include Bristol-Myers Squibb, Merck, AstraZeneca, Roche, and Novartis. Other companies such as Pfizer, AbbVie, and Johnson & Johnson are also involved in the development of these drugs. Show Less Read more